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background: Recently, proteomic technologies have demonstrated that several proteins are differently expressed in various body
ﬂuids of patients with endometriosis compared with those without this condition. The aim of this study was to investigate proteins secreted
in urine of patients with endometriosis using proteomic techniques in order to identify potential markers for the clinical diagnosis of endo-
metriosis.
methods: Urine samples were collected from women undergoing laparoscopy for different indications including pelvic masses, pelvic
pain, suspicious endometriosis, infertility and diagnostic evaluation. Proteomic techniques and mass spectrometry were used to identify pro-
teins secreted in the urine of the patients with and without endometriosis and quantiﬁcation of identiﬁed protein was performed using
western blot and speciﬁc commercial sandwich enzyme-linked immunosorbent assays (ELISA).
results: Twenty-two protein spots were differentially expressed in the urine of patients with and without endometriosis, one of which
was identiﬁed as urinary vitamin D-binding protein (VDBP). ELISA quantiﬁcation of urinary VDBP corrected for creatinine expression (VDBP-
Cr) revealed that urinary VDBP-Cr was signiﬁcantly greater in patients with endometriosis than in those without (111.96+74.59 versus
69.90+ 43.76 ng/mg Cr, P ¼ 0.001). VDBP-Cr had limited value as a diagnostic marker for endometrioisis (Sensitivity 58%, Speciﬁcity
76%). When combined with serum CA-125 levels (the product of serum CA-125 and urinary VDBP-Cr), it did not signiﬁcantly increase
the diagnostic power of serum CA-125 alone.
conclusions: Urinary VDBP levels are elevated in patients with endometriosis. They have limited value as a potential diagnostic bio-
marker for endometriosis but suggest it would be worthwhile to investigate other urinary proteins for this purpose.
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Introduction
Endometriosis is deﬁned as the proliferation of endometrial tissue
outside the uterine cavity and is one of the most common benign
gynecologic disorders. This disease is present in 10% of all
reproductive-aged women, and its prevalence increases from 20 to
50% in infertile women (Taylor et al., 2002). However, diagnosis of
endometriosis is often difﬁcult due to the fact that there is no deﬁnite
diagnostic biomarker yet available. Imaging techniques, such as ultra-
sound and magnetic resonance imaging, have been shown to be unre-
liable in the diagnosis or staging of this disease. Therefore, the direct
visualization of lesions and histologic conﬁrmation through surgical
procedures are currently essential for the deﬁnitive diagnosis of
endometriosis. Although laparoscopy is a minimally invasive proced-
ure, it requires general anesthesia, developed surgical skills and pro-
cedural costs. Additionally, laparoscopy is associated with the risk of
potential complications.
Despite numerous investigative efforts and recent advances in the
understanding of the molecular basis of endometriosis, a substantial
gap remains in the development of effective non-invasive diagnostic
biomarkers for endometriosis diagnosis. Therefore, newly available
technologies could play a key role in the identiﬁcation of novel bio-
logical markers in the early stages of endometriosis. Recently,
several investigators have advocated the use of proteomic technolo-
gies in endometriosis research and have demonstrated that several
proteins are differently expressed in various body ﬂuids, including
& The Author 2011. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Reproduction, Vol.27, No.2 pp. 515–522, 2012





















serum, plasma, peritoneal and endometrial ﬂuids and urine of patients
with endometriosis versus those without this condition (Ametzazurra
et al., 2009; Ferrero et al., 2007; Liu et al., 2007; Seeber et al., 2010;
Tokushige et al., 2011). Proteomic approaches enable the comparison
of protein expression in cells, tissues or body ﬂuids under various con-
ditions. The study of protein function and protein–protein interactions
may provide more information about the disease than the application
of genomics tools because a low correlation exists between the geno-
type and phenotype in endometriosis (Poliness et al., 2004).
Biomarkers in urine would be ideal because this ﬂuid is easily
obtained in relatively large quantities using non-invasive procedures.
The clinical importance of urinary angiogenic factors and cytokines
has been demonstrated not only in urogenital diseases, but also in
other systemic diseases including heart failure and brain tumors
(Matsumoto and Kanmatsuse, 2001; Dvorak, 2002; Rivera et al.,
2004; Buhimschi et al., 2005; Cho et al., 2007; Smith et al., 2008).
Recent studies also indicate that proteomic analysis of urine may
lead to new potential biomarkers for various systemic diseases such
as ovarian cancer and coronary artery disease (Ye et al., 2006; Zim-
merli et al., 2008). We have previously demonstrated the signiﬁcance
of urinary angiogenic factors in patients with endometriosis (Cho et al.,
2007). We therefore hypothesized that certain proteins might be dif-
ferentially excreted in the urine of women with endometriosis com-
pared with those without. The purpose of this study was to
conduct comparative proteomic analysis of urine between patients
with and without endometriosis and to identify novel potential
urinary biomarkers for endometriosis.
Materials and Methods
Study population and sample collection
Ninety-ﬁve patients aged 20–47 years participated in this study after giving
written informed consent. The study was approved by the Institutional
Review Board of Gangnam Severance Hospital. All patients included in
the study underwent laparoscopy for various indications including pelvic
masses, pelvic pain, suspicious endometriosis, infertility and diagnostic
evaluation between January 2008 and October 2010. Pretreatment
serum CA-125 levels in all patients were measured using CA-125 II elec-
trochemiluminescence immunoassay with the Roche/Hitachi Modular
Analytics E170 system (Roche Diagnostics, Tokyo, Japan). At the time
of surgery, all possible endometriotic lesions were excised and sent to
pathology for conﬁrmation of diagnosis. Patients were assigned to the
endometriosis group only after pathologic conﬁrmation of excised tissue.
The extent of endometriosis was determined using the American
Society of Reproductive Medicine (ASRM) revised classiﬁcation (American
Society for Reproductive Medicine, 1997). Fifty-seven patients had histolo-
gically conﬁrmed endometriosis: 5 patients were classiﬁed with
minimal-to-mild disease (Stages I and II) and 52 patients with
moderate-to-severe disease (Stages III and IV). Thirty-eight patients parti-
cipated as controls, and this group included 18 cases of dermoid cysts and
20 cases of benign ovarian cysts including serous cystadenoma and paratu-
bal cyst. Exclusion criteria included post-menopausal status; previous
hormone or gonadotrophin-releasing hormone (GnRH) agonist use; ade-
nomyosis; endometrial cancer; hyperplasia or endometrial polyps; infec-
tious diseases; chronic or acute inﬂammatory diseases; malignancy;
autoimmune disease and cardiovascular disease. Although no effort was
made to control for or assess dietary calcium or vitamin D intake, concur-
rent medication use, including calcium or vitamin D supplements, was
recorded and excluded for ﬁnal analysis. The menstrual cycle stage was
recorded for each patient, including proliferative phase, beginning of
menses until 14 days before the next menses, secretory phase and
1–13 days before the next menses.
Urine samples were collected from 57 women with histologically proven
endometriosis and 38 women for whom histological or laparoscopic evi-
dence indicated endometriosis was not present. Each urine sample
(20 ml) was collected into a sterile plastic tube when the bladder was
catheterized after induction of anesthesia and 1X protease inhibitor cock-
tail was added (Roche, Germany). Urine samples were immediately centri-
fuged at 1000g for 10 min and sediment-free urine samples were obtained.
Urine aliquots were frozen at 2808C until used for further analysis.
Because previous studies have demonstrated that the collection of 24-h
and ﬁrst-morning urine is less practical for proteomic analysis and may
be contaminated with proteins from overgrown bacteria or bladder epi-
thelial cells, no effort was made to obtain samples at a speciﬁc time of
day (Bottini et al., 2002; Hoorn et al., 2005).
Proteomics
Urine samples from four endometriosis patients and four without endo-
metriosis were used for proteomics analysis. Each urine sample (20 ml)
was concentrated to 0.5 ml using Vivaspin (2,000 MW cut-off; Sartorius,
Hannover, Germany) and proteins in the concentrated urine were preci-
pitated using a ReadyPrep 2-D cleanup kit (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) according to the manufacturer’s instructions. The
resulting protein pellets were completely dissolved in 2-D buffer (7 M
urea, 2 M thiourea, 0.4% [w/v] dithiothreitol and 4% [w/v] CHAPS)
and centrifuged at 13 000g for 15 min. Protein concentrations in the
supernatants were determined by the Bradford method.
For one-dimensional electrophoresis, 450 mg of urine proteins from
each sample were rehydrated overnight at room temperature onto
linear pH 4–7 (18-cm) Immobiline Dry Strips (GE Healthcare) with
0.8% carrier ampholyte (pH 4–7) and 0.005% (w/v) Bromophenol
Blue. The rehydrated Dry Strips were focused a total of 48 kVh using a
Multiphor II apparatus (GE Healthcare). The focused Dry Strips were
reduced in 5 mM tributyl-phosphine and 15 mM acrylamide for 15 min
each at ambient temperature.
The 2-D separations were performed on 8–16% (v/v) linear gradient
SDS-polyacrylamide gels. After protein separation, gels were ﬁxed for
1 h in a solution of 40% (v/v) methanol containing 5% (v/v) phosphoric
acid and stained with Colloidal Coomassie Blue G-250 solution (Proteo-
meTech, Seoul, Korea) overnight. The gels were destained in 1% (v/v)
acetic acid for 4 h and then imaged using a GS-710 imaging calibrated
densitometer (Bio-Rad, Hercules, CA, USA). For the determination of dif-
ferential protein expression levels, the scanned images of women with and
without endometriosis were analysed and compared using ImageMaster V
software (GE Healthsciences).
Protein identiﬁcation by LC-MS/MS
Protein spots of interest were excised from the gels and destained in 1:1
(v/v) acetonitrile/50 mM ammonium bicarbonate (pH 7.8), dried and
10 ml trypsin solution was then added (12 ng/ml, Promega, Madison,
WI, USA). After discarding excess trypsin and adding 20 ml of 50 mM am-
monium bicarbonate, the gels were incubated overnight at 378C. The
tryptic digest solutions were concentrated and cleaned up using a C18
microcolumn (Millipore, Billerica, MA, USA) as instructed by the
manufacturer.
The resulting tryptic peptides were separated and analyzed using a
reversed phase capillary HPLC directly coupled to a Finnigan LCQ ion
trap mass spectrometer (LC-MS/MS) (Bahk et al., 2004). Both a 0.1 ×
20-mm trapping and a 0.075 × 130-mm resolving column were packed





















with Vydac 218 MS low triﬂuoroacetic acid C18 beads (5 mm in size,
300 A˚ in pore size; Vydac, Hesperia, CA, USA) and placed in line. The
peptides were then bound to the trapping column for 10 min with 5%
(v/v) aqueous acetonitrile containing 0.1% (v/v) formic acid. The bound
peptides were eluted with a 50-min gradient of 5–80% (v/v) acetonitrile
containing 0.1% (v/v) formic acid at a ﬂow rate of 0.2 ml/min. For tandem
mass spectrometry, each scan cycle included a full mass scan range mode
(m/z 300–2000 Da) and up to three product ion scans with a relative col-
lision energy of 55%. The individual MS/MS spectrum was processed using
the Bioworks 3.3 software (Thermo Fisher, San Jose, CA, USA). The gen-
erated peak list ﬁles were used to query the NCBI human database using
the MASCOT program (http://www.matrixscience.com). Search para-
meters included variable modiﬁcations of methionine (oxidation) and cyst-
eine (propionamide), peptide mass tolerance at 2 Da, MS/MS ion mass
tolerance at 1 Da, allowance of missed cleavage at 1 and charge states
(+1, +2, and +3). Matches of peptide(s) with only signiﬁcant hits as
deﬁned by MASCOT probability analysis were accepted.
Western blot
The urine from eight samples (four endometriosis and four control
patients), which were distinct from those subjected to 2-DE analyses,
were quantiﬁed using a BCA assay (Pierce, Rockford, IL, USA). For
western blot analyses, equal amounts of urine proteins (70 mg) were sub-
jected to electrophoresis on a 4–20% gradient polyacrylamide gel (Koma
Biotech, Seoul, Korea) and transferred to PVDF membranes over 50 min
at 15 V using a EZway blotting system (Koma Biotech). Blots were blocked
for 1 h at room temperature with 3% (w/v) non-fat dried milk in tris-
buffered saline (TBS) solution containing 0.1% Tween-20 (TBS-T). After
three washes with TBS-T, the blots were incubated at 48C overnight
with vitamin D-binding protein (VDBP; Santa Cruz Biotechnology, Santa
Cruz, CA, USA; sc-69771) antibody at a dilution of 1:700 in
TBS-T. Membranes were washed with TBS-T solution and incubated
with horseradish peroxidase-conjugated goat anti-mouse IgG (Invitrogen,
Carlsbad, CA, USA) at a 1:2000 dilution at room temperature for 1 h.
Immunoreactive proteins were detected by chemiluminescent reaction fol-
lowed by exposure of the membranes to hyperﬁlm ECL (Amersham Phar-
macia Biotech, Inc., Little Chalfont, UK). The relative density of the protein
bands was quantiﬁed by Gel Doc XR+ (Bio-Rad).
Enzyme-linked immunosorbent assay
(ELISA)
The concentration of VDBP in urine (100 ml, diluted 1:2) was measured
using speciﬁc commercial sandwich enzyme-linked immunosorbent
assays (ELISAs) according to the manufacturer’s protocols (ALPCO Diag-
nostics, Salem, NH, USA; enzyme immunoassay no. 30-2314) and
expressed in ng/dl. The minimal detectable concentration for urinary
VDBP was 1.23 ng/ml. Urine creatinine (Cr) levels were measured with
commercial assays at Gangnam Severance Hospital (Hitachi 7600-110,
Tokyo, Japan). Urine VDBP values were normalized to urine Cr concentra-
tions and expressed as VDBP-to-Cr ratio (VDBP-Cr; nanograms per
miligrams of creatinine).
Statistical analysis
Data were expressed as mean+ SD or median [interquartile (IOR)
ranges] where appropriate. The clinical and laboratory characteristics of
endometriosis and control group patients, and seasonal variations of
urinary VDBP and VDBP-Cr were compared using Student’s t-test. To
analyze variance in VDBP-Cr over the different menstrual cycle stages,
the Kruskal–Wallis test was used, followed by the Dunn procedure. To
determine if differences in correlations were statistically signiﬁcant,
Pearson’s correlation coefﬁcient or Spearman rank correlation coefﬁcient
was calculated, where appropriate. The diagnostic performance of urinary
VDBP-Cr was assessed using receiver operating characteristic (ROC)
curves (Hanley and McNeil, 1982) to plot the test sensitivity versus its
false-positive rate and determine the usefulness of a diagnostic test over
a range of possible clinical results. The diagnostic utility of the test can
be expressed as the area under the ROC curve (AUC), which was calcu-
lated as a measure of the ability of each potential biomarker to discrimin-
ate between endometriosis and control cases. An AUC of 0.5 indicates
classiﬁcations assigned by chance. Based on ROC analysis, the best statis-
tical cut-off value of VDBP-Cr was calculated, which corresponds to the
point at which the sum of false positives and false negatives is less than
any other point. Sensitivity and speciﬁcity for selected cut-off points
were then assessed. SPSS 16.0 (SPSS Inc, Chicago, IL, USA) was used
for statistical analysis and P, 0.05 was considered statistically signiﬁcant.
Results
Clinical characteristics
The clinical characteristics of patients are shown in Table I. The mean
age (mean+ SD) of endometriosis patients and controls was 34.22+
6.88 and 32.76+ 10.26 years, respectively. There were no signiﬁcant
differences in mean gravidarum, mean parity or mean body mass index
(BMI) between the two groups. In contrast, serum CA-125 levels were
signiﬁcantly higher in patients with endometriosis than in
controls (83.09+ 120.93 versus 20.57+13.25 IU/ml, respectively;
P, 0.001). No signiﬁcant differences were observed in mean urine
creatinine levels between the two groups.
Proteomics
Two-dimensional gels of urinary proteins revealed an average of 512
spots over a pH range of 4.0–7.0. We identiﬁed 22 urinary protein
spots with signiﬁcantly greater expression (% volume) in women
with endometriosis compared with control cases (Fig. 1). Of those
22 up-regulated protein spots on the gels in women with endometri-
osis, 5 spots showed the biggest difference (more than 10-fold in-
crease) compared with women without endometriosis. Five spots
were identiﬁed as prealbumin [isoelectric point (pI) 5.52, Mr 15.90],
enolase-1 (pI 7.01, Mr 47.13), alpha-1 antitrypsin (pI 5.35, Mr
44.25), Chain A solution structure of Bb′ domains of human protein
disulﬁde isomerase (pI 4.84, Mr 25.51) and VDBP (pI 5.40, Mr
........................................................................................







Age (years) 34.2 + 6.88 32.7 + 10.26 0.443
Gravidarum 1.0 + 1.31 1.2 + 1.46 0.448
Parity 0.6 + 0.86 0.6 + 0.86 0.923
BMI (m2/kg) 18.1 + 7.30 17.7 + 7.76 0.809
CA-125 (IU/ml) 83.1 + 120.93 20.6 + 13.25 ,0.001
Urine creatinine
(mg/dl)
103.2 + 52.36 88.4 + 68.83 0.239
Data are expressed as mean + SD.





















52.93) by LC-MS/MS (Table II). The spot with the biggest difference
was VDBP. We decided that VDBP merited further detailed investiga-
tion due to its uniform high abundance in all endometriosis samples
and its known action as a macrophage activator. The intensity of its
expression (% volume) was statistically signiﬁcantly higher in women
with endometriosis, compared with those without endometriosis
(0.2005+ 0.0582 versus 0.0006+ 0.001, respectively, P, 0.001).
Biomarker validation
Western blot analysis of eight urine samples (four samples from
patients with endometriosis and four samples from controls) with a
VDBP-speciﬁc antibody showed that all samples were VDBP positive
(Fig. 2A). Quantiﬁcation of the relative density of the protein bands
indicated that the relative density of urinary VDBP was signiﬁcantly
greater in patients with endometriosis than that in controls (2.48+
0.11 versus 1.15+ 0.26; P, 0.001; Fig. 2B).
ELISA quantiﬁcation of urinary VDBP in 57 patients with endomet-
riosis and 38 patients without endometriosis revealed that urinary
VDBP levels were signiﬁcantly higher in women with endometriosis
than those without (106.12+74.55 versus 58.68+ 60.82 ng/ml,
respectively, P ¼ 0.001) (Fig. 3). After correcting urinary VDBP
levels for creatinine (VDBP-Cr), it was apparent that the levels of
VDBP-Cr were also signiﬁcantly greater in urine of women with
endometriosis than of controls (111.96+ 74.59 versus 69.90+
43.76 ng/mg Cr, respectively; P ¼ 0.001; Fig. 3). Figure 4 shows the
cyclic variation of VDBP-Cr in patients with endometriosis and con-
trols. Data are expressed as median and the IQR. We then evaluated
VDBP-Cr according to the menstrual cycle and found no signiﬁcant dif-
ference between the two groups in the median VDBP-Cr during the
proliferative phase. The median VDBP-Cr in patients with and
without endometriosis during the secretory phase were 91.20 ng/
mg Cr (IQR: 53.31–143.32) and 54.13 ng/mg Cr (IQR: 36.02–
82.14), respectively. The difference between these values was statistic-
ally signiﬁcant (P ¼ 0.042). We also evaluated the correlations
between VBDP-Cr and other clinical features. However, no signiﬁcant
correlations existed between VDBP-Cr and disease severity or serum
CA-125 levels (data not shown). Date of sampling was used to deﬁne
seasonality, as fall/winter (September through February) and spring/
summer (March through August). The mean values of urinary VDBP
and VDBP-Cr were 87.88+ 72.73 ng/ml and 101.41+ 75.06 ng/
mg Cr for spring/summer season and 86.04+74.09 ng/ml and
85.73+52.40 ng/mg Cr for fall/winter and the differences were stat-
istically insigniﬁcant (P ¼ 0.905, P ¼ 0.266, respectively). Therefore,
no seasonal variations were noted in urinary VDBP levels and
VDBP-Cr.
ROC curves were used to assess the utility of VDBP-Cr in diagnos-
ing endometriosis (Fig. 5). The AUC of VDBP-Cr was 0.678 (95% CI:
0.569–0.787), and the optimum cut-off value was 87.83 ng/mg Cr
with 57.9% sensitivity and 76.3% speciﬁcity. We also examined if
VDBP-Cr could improve the diagnostic power of CA-125.The AUC
for CA-125 alone was 0.857 [95% conﬁdence interval (CI): 0.781–
0.933] with sensitivity of 69.6% and speciﬁcity of 91.9%, when
assessed at a cut-off point of 35 IU/ml, which is the most commonly
reported cut-off level in the literature. When CA-125 was combined
with VDBP-Cr by multiplication (CA-125 × VDBP-Cr) the AUC for
the combined marker was 0.874 (95% CI: 0.802–0.945), and with
.............................................................................................................................................................................................
Table II Protein spots with signiﬁcantly different expression (% volume) in urine of women with and without
endometriosis.
Protein pI Mr (kDa) Endometriosis Control P value
Alpha-1 antitrypsin 5.35 44.25 0.082 + 0.0123 0.002 + 0.0020 ,0.001
Chain A, solution structure of Bb′ domains of human protein
disulﬁde isomerase
4.84 25.51 0.112 + 0.0383 0.001 + 0.0020 ,0.001
Enolase-1 7.01 47.13 0.184 + 0.0330 0.001 + 0.0010 ,0.001
Prealbumin 5.52 15.90 0.138 + 0.0273 0.001 + 0.0020 ,0.001
VDBP 5.40 52.93 0.201 + 0.0582 0.001 + 0.0010 ,0.001
Data are expressed as mean + SD.
Figure 1 Proteomic analysis of highly expressed proteins in the
urine of women with endometriosis. Twenty-two spots that were
expressed signiﬁcantly different (% volume) in urine of women with
and without endometriosis were identiﬁed. The protein spot circled
in dotted red is VDBP.





















the optimal cut-off value of 2755 the sensitivity was 73.2% and the
speciﬁcity 97.3%.
Discussion
A number of recently published studies have used proteomic analysis
of urine to identify novel biomarkers for several different diseases.
Zimmerli et al. (2008) developed the coronary artery disease-speciﬁc
panel using urinary proteomics techniques that showed sensitivity and
speciﬁcity of 98% and 83%, respectively, for the prediction of
coronary artery disease. Additionally, Ye et al. (2006) reported
the proteomic-based discovery and characterization of urinary
Figure 4 Urinary VDBP-Cr ratio in the urine of patients with endo-
metriosis and controls according to the menstrual cycle. Urinary
VDBP-Cr levels were signiﬁcantly higher in the urine of patients with
endometriosis than that of controls during the secretory phase of the
menstrual cycle. Data were analyzed by the Kruskal–Wallis test fol-
lowed by the Dunn procedure. Data are represented by
box-and-whisker plots. Boxes indicate the 25th and 75th percentiles,
with a solid line within the box showing the median value. Whiskers
show the largest and smallest observed value that is not an outlier. Out-
liers are shown by circles in the plot and are deﬁned as valuesmore than
1.5 box-lengths from the 25th or 75th percentile. *P ¼ 0.042.
Figure 2 Western blot analysis of eight urine samples probed with
VDBP-speciﬁc antibody (A). The expression of VDBP was signiﬁcantly
greater in urine of patients with endometriosis than that of controls
(B). Data are expressed as mean+ SD. *P, 0.001.
Figure 5 ROC curves of serum CA-125, urinary VDBP-Cr and the
combined marker. Serum CA-125 levels were multiplied by VDBP-Cr
ratio for the differential diagnosis of patients with endometriosis and
controls.
Figure 3 Urinary VDBP levels and VDBP-Cr ratio in the urine of
patients with endometriosis and controls. Data are expressed as
mean+ SD. *P ¼ 0.001.





















glycosylated eosinophil-derived neurotoxin and COOH-terminal
osteopontin fragments for ovarian cancer. More recently, urinary
proteomic techniques have been applied in the discovery of biomar-
kers for endometriosis, and cytokeratin-19, which is known to be a
cell structural protein and a member of type I cytokeratin protein
genes, has been identiﬁed in the urine of patients with endometriosis
(Tokushige et al., 2011).
In this study, we found that urinary VDBP is signiﬁcantly increased in
patients with endometriosis. VDBP is a group-speciﬁc component of
Gc-globulin and is the major plasma carrier protein of vitamin D meta-
bolites, as it is responsible for the transport of cholecalciferol (vitamin
D3) to the liver, 25-OH-D to the kidneys and 1,25-OH-D (calcitriol,
the active form of vitamin D) to target organs (Daiger et al., 1975).
However, ,5% of circulating VDBP is complexed with vitamin D
metabolites, which leaves a considerable amount of the protein avail-
able for other functions that are closely related to the pathogenesis of
endometriosis. Previous research has shown that this protein is
involved in the transportation of fat and endotoxins, and is known
to be an important factor in the actin scavenging system (Berger and
Beger, 1987; Williams et al., 1988; Lee and Galbraith, 1992). In add-
ition, there is a growing body of evidence suggesting that VDBP plays
an important role in the immune system by acting as a chemotactic
factor to recruit neutrophils, monocytes and ﬁbroblasts (Kew and
Webster, 1988; Perez et al., 1988; Piquette et al., 1994). Also, at
sites of inﬂammation, sequential contact of VDBP with B and T cells
is able to convert VDBP into a potent macrophage-activating factor
(Yamamoto and Naraparaju, 1996). Therefore, our results showing
increased VDBP expression in urine from patients with endometriosis
may be related to the typical systemic subclinical inﬂammatory process
involved with endometriosis (Agic et al., 2006). Adding to the biologic-
al plausibility that VDBP is connected with the pathogenesis of
endometriosis is the fact that hormones such as estrogen and
interleukin-1, which are known to be involved with endometriosis, in-
ﬂuence the concentration of Gc-globulin (Guha et al., 1995; Rejnmark
et al., 2002).
Despite the important and diverse roles of VDBP, few studies have
evaluated its expression in endometriosis. One study showed no sig-
niﬁcant differences in the amount of serum and peritoneal ﬂuid VDBP
between women with and without endometriosis, whereas Agic et al.
(2007) demonstrated that vitamin D receptor and its hydroxylases
were expressed in the endometrium and ovaries of women with
and without endometriosis and hypothesized that vitamin D might in-
ﬂuence the local activity of immune cells, and cytokines thought to play
important pathogenic roles in the development and maintenance of
endometriosis (Agic et al., 2007; Borkowski et al., 2008). Another
study, using high-resolution two-dimensional gel electrophoresis,
reported that one isoform of VDBP was signiﬁcantly lower in the peri-
toneal ﬂuid of women with endometriosis than that of controls and
that the expression was further decreased following the treatment
with GnRH agonist (Ferrero et al., 2005; Ferrero et al., 2009). More
recently, proteomic analysis of serum using two-dimensional differ-
ence gel electrophoresis showed that the concentration of VDBP is
elevated in endometriosis patients and suggested that the inability to
sufﬁciently activate the phagocytic function of macrophages in patients
carrying the GC*2 polymorphism may be associated with the
implantation of endometriotic tissues in the peritoneal cavity (Faserl
et al., 2011).
Evaluation of urinary VDBP has been reported previously, and pre-
vious studies indicated that long-term cadmium exposure and type I
diabetes are associated with high levels of urinary VDBP (Uchida
et al., 2007; Thrailkill et al., 2011). Our results showed that urinary
VDBP levels are increased in patients with endometriosis. We also
evaluated urinary VDBP based on stages of the menstrual cycle and
found that the amount of VDBP was signiﬁcantly higher in patients
with endometriosis than that in controls during the secretory phase
of the menstrual cycle. However, we found no signiﬁcant cyclic vari-
ation in urinary VDBP in either the endometriosis group or the
control group. There are no previous studies showing the cyclic varia-
tions of urinary VBDP, but our ﬁndings are consistent with results
showing that plasma VDBP expression is not related to menstrual
cycle phase (Nielsen et al., 1990; Ferrero et al., 2005).
Another interesting marker shown to be increased in urine of
patients with endometriosis in this study was enolase-1. Enolase-1 is
a glycolytic enzyme that binds plasminogen at the cell surface, enhan-
cing local plasmin production and migration of monocyte to sites of
inﬂammation (Miles et al., 1991). Recent evidence shows that
enolase-1 promotes plasminogen-mediated recruitment of monocytes
to the acutely inﬂamed lung and anti-a-enolase antoantibody was
identiﬁed as a potential serum marker for endometriosis (Nabeta
et al., 2009; Wygrecka et al., 2009). Therefore, further validation of
this marker in urine of patients with endometriosis needs to be con-
sidered in the near future.
One potential limitation of this study is related to the patients
included in the control group. Healthy women without pelvic pain
or disease would have been an ideal comparison group to distinguish
between endometriosis and normal patients. However, choosing ad-
equate control groups is a complex and often overlooked problem
in endometriosis research. Although we only included patients in
the control group surgically proved to be free of endometriosis, the
majority of our control group had various other benign diseases,
which may have different effects on the levels of urinary VDBP.
Another point that needs to be addressed is the discrepancy
between the relative expression of urinary VDBP as measured by pro-
teomics and that of which is determined by western blot or ELISA.
Such discrepancy has been shown in previous study (Jou et al.,
2010). Due to the characteristics of two-dimensional electrophoresis,
trailing of protein spots may occur in pI focusing and may decrease the
separation power. Furthermore, this effect may lead to blurring of the
protein spots and make the images different while image analyzing.
Therefore, it is necessary to conﬁrm and validate the data obtained
from gel electrophoresis by protein blotting, as we did in this study.
To the best of our knowledge, this study is the ﬁrst to report the
identiﬁcation and validation of VDBP as a urinary biomarker in detect-
ing endometriosis. Although urinary VDBP levels were signiﬁcantly
increased in patients with endometriosis than those without, they
have limited potential as a diagnostic biomarker for endometriosis
even alone or after combining with serum CA-125. Addition of
VDBP-Cr to CA-125 made no signiﬁcant difference to the AUC in
the ROC curve and some of the slight improvement in sensitivity
and speciﬁcity may have been because the cut-off for CA-125 was
the generally accepted value, whereas that for the combined data
was the optimum for this data set. The lack of diagnostic power
was disappointing since only a small number of patients included in
this study had minimal-to-mild disease. The expression of VDBP has





















been reported in the uterus, serum and the peritoneal ﬂuids but it is
unclear why or how VDBP is speciﬁcally excreted in urine (Cooke
et al., 1991; Ferrero et al., 2005; Borkowski et al., 2008; Ferrero
et al., 2009). Further research is warranted to investigate the possible
role of VDBP and other urinary proteins in the pathogenesis and diag-
nosis of endometriosis.
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